OTCMBXRXQ
Market cap0kUSD
Dec 20, Last price
0.00USD
1D
0.00%
1Q
0.00%
IPO
-100.00%
Name
Baudax Bio Inc
Chart & Performance
P/E
—
P/S
0.00
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
-44.81%
Rev. gr., 5y
0.00%
Revenues
1m
+17.50%
Net income
-59m
L+197.41%
CFO
-28m
L-43.59%
Profile
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMBA, which is in phase I clinical trial; BX3000, an NMBA reversal agent; and Dex-IN, a proprietary intranasal formulation of dexmedetomidine. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | ||||||
Revenues | 1,269 17.50% | 1,080 119.07% | ||||
Cost of revenue | 35,015 | 5,570 | ||||
Unusual Expense (Income) | ||||||
NOPBT | (33,746) | (4,490) | ||||
NOPBT Margin | ||||||
Operating Taxes | 23,052 | 3,843 | ||||
Tax Rate | ||||||
NOPAT | (56,798) | (8,333) | ||||
Net income | (58,795) 197.41% | (19,769) -74.02% | ||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 20,396 | 30,727 | ||||
BB yield | -1,934.12% | -182.92% | ||||
| Debt | ||||||
Debt current | 5,600 | 2,222 | ||||
Long-term debt | 1,519 | 6,309 | ||||
Deferred revenue | ||||||
Other long-term liabilities | 11,295 | 18,096 | ||||
Net debt | 1,860 | (7,360) | ||||
| Cash flow | ||||||
Cash from operating activities | (27,793) | (49,270) | ||||
CAPEX | (20) | (203) | ||||
Cash from investing activities | (20) | (194) | ||||
Cash from financing activities | 17,181 | 35,013 | ||||
FCF | (42,974) | (7,713) | ||||
| Balance | ||||||
Cash | 5,259 | 15,891 | ||||
Long term investments | ||||||
Excess cash | 5,196 | 15,837 | ||||
Stockholders' equity | (190,888) | (131,106) | ||||
Invested Capital | 185,060 | 170,959 | ||||
ROIC | ||||||
ROCE | 579.03% | |||||
| EV | ||||||
Common stock shares outstanding | 332 | 55 | ||||
Price | 3.18 -98.96% | 306.88 -78.30% | ||||
Market cap | 1,055 -93.72% | 16,798 -10.78% | ||||
EV | 2,915 | 9,438 | ||||
EBITDA | (31,584) | (1,674) | ||||
EV/EBITDA | ||||||
Interest | 21,070 | 2,303 | ||||
Interest/NOPBT | ||||||